Open an account

Aura Biosciences

AURA · NASDAQ

$6.56+$0.27 (+4.29%)TodayMarket closed ·
Prev close $6.29

About AURA

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

Employees
113
Headquarters
Boston, Massachusetts
Listed
Oct 29, 2021
Sector
Health Care
Industry
Biotechnology
Website
aurabiosciences.com

AURA key statistics

Market cap
680.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
935.12K
Volume
1.16M
Open price
$6.32
High today
$6.77
Low today
$6.18
52 Week high
$9.54
52 Week low
$4.73

Aura Biosciences (AURA) at a glance

Aura Biosciences (AURA) last traded at $6.56, with a market cap of 680.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.18 and $6.77. The current price is 6.1% above the day's low and 3.1% below its high.

Volume so far is 1.16M shares, above the average of 935.12K shares a day.

Over the past year Aura Biosciences has ranged from $4.73 to $9.54, and now sits 38% of the way up that range.

Aura Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.48 per share against an estimate of -$0.3815.

The average analyst price target is $16.93, 158.1% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $16.93
Low
$12.12
Now
$6.56
High
$24.15

AURA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 12.5% on average.

  1. Q3 FY24: reported -$0.42 per share against an estimate of -$0.4494
  2. Q4 FY24: reported -$0.52 per share against an estimate of -$0.4524
  3. Q1 FY25: reported -$0.55 per share against an estimate of -$0.501
  4. Q2 FY25: reported -$0.47 per share against an estimate of -$0.4667
  5. Q3 FY25: reported -$0.40 per share against an estimate of -$0.4758
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.4361
  7. Q1 FY26: reported -$0.50 per share against an estimate of -$0.4055
  8. Q2 FY26: reported -$0.48 per share against an estimate of -$0.3815

AURA news

  • Rishabh Mishra

    US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert

  • Vandana Singh

    Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Similar companies

Companies in the same industry as Aura Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.